Scorpion Therapeutics Accelerates Precision Oncology 2.0 for More Patient Populations
Read More
Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of STX-478, Its Mutant-Selective PI3Kα Inhibitor for the Treatment of Breast Cancer and Other Solid Tumors
More Info
In The News
Sanofi’s Michael Streit Departs to be Cancer-focused Scorpion’s First CMO
Read More
Fierce Biotech’s 2022 Fierce 15
Read More
Axel Hoos Wants to Take Small Molecules Further at Scorpion, Leaving Big Pharma in the Dust
Read More
Weixue Wang: This Assay Inventor Identifies Drug Candidates for Targets Once Thought to be Undruggable
Read More
The Endpoints 11: They’ve Got Mad Money And Huge Ambitions. It’s Time To Go Big Or Go Home
Read More
Up And Down The Ladder: The Latest Comings And Goings
Read More
GSK’s Head Of Oncology Jumps To Boston Precision Medicine Startup
Read More
GSK’s Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion
Read More
In GSK’s Hoos, Scorpion Gains Oncology Pathfinder To Match Its $270m War Chest
Read More
GSK Oncology Exec Hoos Heads Back To Biotech As CEO Of Scorpion Therapeutics
Read More
Axel Hoos, The Keeper Of The Oncology Flame At Glaxosmithkline, Steps Away For His Next Challenge At Tiny Scorpion
Read More
J.P. Morgan 39th Annual Healthcare Conference
Read More
Scorpion Therapeutics Strikes Major $162m Funding Round For ‘Precision Oncology 2.0™’
Read More
With Biotech Funding At ‘All-time High,’ Scorpion Scoops Up $162 Million
Read More
Gary Glick, Keith Flaherty Now Have $270m To Realize Their Vision For Precision Oncology 2.0™ — We’ll Just Have To Wait For The Details
Read More
Scorpion Therapeutics Debuts With $108m To ‘put The Sting In Cancer’
Read More
Scorpion, Seeking To Develop ‘Precision Medicine’ Drugs For Cancer, Debuts With $108m In Funding
Read More
What Can A Biotech Entrepreneur And A Top Scientist Come Up With On A Couple Of Shared Flights? Well…
Read More
Media
STX-478, a mutant-selection PI3Kα inhibitor clinical candidate with a best-in-class-profile
Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile
Discovery and characterization of a PI3KαH1047X mutant selective inhibitor with a best-in-class profile
Press Releases
Scorpion Therapeutics Accelerates Precision Oncology 2.0 for More Patient Populations
Read More
Sanofi’s Michael Streit Departs to be Cancer-focused Scorpion’s First CMO
Read More
Fierce Biotech’s 2022 Fierce 15
Read More
Axel Hoos Wants to Take Small Molecules Further at Scorpion, Leaving Big Pharma in the Dust
Read More
Weixue Wang: This Assay Inventor Identifies Drug Candidates for Targets Once Thought to be Undruggable
Read More
The Endpoints 11: They’ve Got Mad Money And Huge Ambitions. It’s Time To Go Big Or Go Home
Read More
Up And Down The Ladder: The Latest Comings And Goings
Read More
GSK’s Head Of Oncology Jumps To Boston Precision Medicine Startup
Read More
GSK’s Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion
Read More
In GSK’s Hoos, Scorpion Gains Oncology Pathfinder To Match Its $270m War Chest
Read More
GSK Oncology Exec Hoos Heads Back To Biotech As CEO Of Scorpion Therapeutics
Read More
Axel Hoos, The Keeper Of The Oncology Flame At Glaxosmithkline, Steps Away For His Next Challenge At Tiny Scorpion
Read More
J.P. Morgan 39th Annual Healthcare Conference
Read More
Scorpion Therapeutics Strikes Major $162m Funding Round For ‘Precision Oncology 2.0™’
Read More
With Biotech Funding At ‘All-time High,’ Scorpion Scoops Up $162 Million
Read More
Gary Glick, Keith Flaherty Now Have $270m To Realize Their Vision For Precision Oncology 2.0™ — We’ll Just Have To Wait For The Details
Read More
Scorpion Therapeutics Debuts With $108m To ‘put The Sting In Cancer’
Read More
Scorpion, Seeking To Develop ‘Precision Medicine’ Drugs For Cancer, Debuts With $108m In Funding
Read More
What Can A Biotech Entrepreneur And A Top Scientist Come Up With On A Couple Of Shared Flights? Well…
Read More